Oral bioavailability of silymarin formulated as a novel 3-day delivery system based on porous silica nanoparticles

Acta Biomaterialia

Volumn 8, Issue 6, 2012, Pages 2104-2112

  Cao, Xia ^a   Fu, Min ^a   Wang, Liang ^a   Liu, Hongfei ^a   Deng, Wenwen ^a   Qu, Rui ^a   Su, Weiyan ^a   Wei, Yawei ^a   Xu, Ximing ^a   Yu, Jiangnan ^a  

^a JIANGSU UNIVERSITY   (China)

Author keywords

Bioavailability; Controlled release; Poorly soluble drug; Porous silica nanoparticles; Silymarin

Indexed keywords

BIOCHEMISTRY; CONTROLLED DRUG DELIVERY; DRUG PRODUCTS; FLAVONOIDS; MICROEMULSIONS; TARGETED DRUG DELIVERY;

CONTROLLED RELEASE; DELIVERY SYSTEMS; ORAL BIOAVAILABILITIES; POORLY SOLUBLE DRUGS; POORLY WATER-SOLUBLE DRUGS; POROUS SILICA; POROUS SILICUM NANOPARTICLE; SILICA NANOPARTICLES; SILYMARIN; SUSTAINED RELEASE;

SILICA NANOPARTICLES;

DRUG CARRIER; EUDRAGIT; HYDROXYPROPYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE; NANOPARTICLE; PHOSPHATIDYLCHOLINE; POROUS SILICA NANOPARTICLE; POVIDONE; SILYMARIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA POSTREMA; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; FEASIBILITY STUDY; GEL; HUMAN; HYDROPHILICITY; IN VITRO STUDY; MALE; MICROEMULSION; NONHUMAN; PRIORITY JOURNAL; SUSTAINED RELEASE FORMULATION; TABLET FORMULATION;

CANIS FAMILIARIS;

EID: 84862818884     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2012.02.011     Document Type: Article

References (40)

1. J. Pepping Milk thistle: Silybum marianum Am J Health Syst Pharm 56 1999 1195 1197
2. K. Flora, M. Hahn, H. Rosen, and K. Benner Milk thistle (Silybum marianum) for the therapy of liver disease Am J Gastroenterol 93 1998 139 143
3. S. Luper A review of plants used in the treatment of liver disease: part 1 Altern Med Rev 3 1998 410 421
4. T. Ding, S. Tian, Z. Zhang, D. Gu, Y. Chen, and Y. Shi Determination of active component in silymarin by RP-LC and LC/MS J Pharm Biomed Anal 26 2001 155 161
5. F. Kvasnicka, B. Biba, R. Sevcik, M. Voldrich, and J. Kratka Analysis of the active components of silymarin J Chromatogr A 990 2003 239 245
6. Blumenthal M, Goldberg A, Brinckmann J. Herbal medicine. Expanded commission E monographs: integrative medicine communications; 2000.
7. Wachter W, Zaeske H. Process for the manufacture of flavanolignan preparation with improved release and absorbability, compositions obtainable thereby and their use for the preparation of pharmaceuticals. US Patent 6020, 384; 2000.
8. D. Voinovich, B. Perissutti, L. Magarotto, D. Ceschia, P. Guiotto, and A. Bilia Solid state mechanochemical simultaneous activation of the constituents of the Silybum marianum phytocomplex with crosslinked polymers J Pharm Sci 98 2009 215 228
9. X. Yan-yu, S. Yun-mei, C. Zhi-peng, and P. Qi-neng Preparation of silymarin proliposome: a new way to increase oral bioavailability of silymarin in beagle dogs Int J Pharm 319 2006 162 168
10. J.W. Wu, L.C. Lin, S.C. Hung, C.W. Chi, and T.H. Tsai Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application J Pharm Biomed Anal 45 2007 635 641
11. N. Barzaghi, F. Crema, G. Gatti, G. Pifferi, and E. Perucca Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects Eur J Drug Metab Pharmacokinet 15 1990 333 338
12. P. Morazzoni, M. Magistretti, C. Giachetti, and G. Zanolo Comparative bioavailability of silipide, a new flavanolignan complex, in rats Eur J Drug Metab Pharmacokinet 17 1992 39 44
13. N. Sun, X. Wei, B. Wu, J. Chen, Y. Lu, and W. Wu Enhanced dissolution of silymarin/polyvinylpyrrolidone solid dispersion pellets prepared by a one-step fluid-bed coating technique Powder Technol 182 2008 72 80
14. S. Tong, C. Chu, Y. Wei, L. Wang, X. Gao, and X. Xu Preparation and effects of 2,3-dehydrosilymarin, a promising and potent antioxidant and free radical scavenger J Pharm Pharmacol 63 2011 238 244
15. C. Chu, S. Tong, Y. Xu, L. Wang, M. Fu, and Y. Ge Proliposomes for oral delivery of dehydrosilymarin: preparation and evaluation in vitro and in vivo Acta Pharmacol Sin 32 2011 973 980
16. W. Wu, Y. Wang, and L. Que Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system Eur J Pharm Biopharm 63 2006 288 294
17. X. Yanyu, S. Yunmei, C. Zhipeng, and P. Qineng The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats Int J Pharm 307 2006 77 82
18. Y. Zhu, J. Yu, S. Tong, L. Wang, M. Peng, and X. Cao Preparation and in vitro evaluation of povidone-sodium cholate-phospholipid mixed micelles for the solubilization of poorly soluble drugs Arch Pharm Res 33 2010 911 917
19. M.S. El-Samaligy, N.N. Afifi, and E.A. Mahmoud Evaluation of hybrid liposomes-encapsulated silymarin regarding physical stability and in vivo performance Int J Pharm 319 2006 121 129
20. M. Van Speybroeck, V. Barillaro, T. Do Thi, R. Mellaerts, J. Martens, and J. Van Humbeeck Ordered mesoporous silica material SBA-15: a broad-spectrum formulation platform for poorly soluble drugs J Pharm Sci 98 2009 2648 2658
21. F. Balas, M. Manzano, P. Horcajada, and M. Vallet-Reg Confinement and controlled release of bisphosphonates on ordered mesoporous silica-based materials J Am Chem Soc 128 2006 8116 8117
22. T. Heikkila, J. Salonen, J. Tuura, M. Hamdy, G. Mul, and N. Kumar Mesoporous silica material TUD-1 as a drug delivery system Int J Pharm 331 2007 133 138
23. T. Ukmar, M. Gaberšček, F. Merzel, and A. Godec Modus operandi of controlled release from mesoporous matrices: a theoretical perspective Phys Chem Chem Phys 13 2011 15311 15317
24. P. Horcajada, A. Ramila, J. Perez-Pariente, and M. Vallet-Reg Influence of pore size of MCM-41 matrices on drug delivery rate Micro Meso Mater 68 2004 105 109
25. T. Ukmar, U. Maver, O. Planinšek, V. Kaučič, M. Gaberšček, and A. Godec Understanding controlled drug release from mesoporous silicates: theory and experiment J Control Release 155 2011 409 417
26. S.W. Song, K. Hidajat, and S. Kawi Functionalized SBA-15 materials as carriers for controlled drug delivery: influence of surface properties on matrix-drug interactions Langmuir 21 2005 9568 9575
27. Z.Z. Li, L.X. Wen, L. Shao, and J.F. Chen Fabrication of porous hollow silica nanoparticles and their applications in drug release control J Controlled Release 98 2004 245 254
28. J.F. Chen, H.M. Ding, J.X. Wang, and L. Shao Preparation and characterization of porous hollow silica nanoparticles for drug delivery application Biomaterials 25 2004 723 727
29. Q. He, J. Zhang, F. Chen, L. Guo, Z. Zhu, and J. Shi An anti-ROS/hepatic fibrosis drug delivery system based on salvianolic acid B loaded mesoporous silica nanoparticles Biomaterials 31 2010 7785 7796
30. L.M. Bimbo, E. Makila, T. Laaksonen, V.P. Lehto, J. Salonen, and J. Hirvonen Drug permeation across intestinal epithelial cells using porous silicon nanoparticles Biomaterials 32 2010 2625 2633
31. L.M. Bimbo, M. Sarparanta, H.A. Santos, A.J. Airaksinen, E. Makila, and T. Laaksonen Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats ACS nano 4 2010 3023 3032
32. J. Yu, Y. Zhu, L. Wang, M. Peng, S. Tong, and X. Cao Enhancement of oral bioavailability of the poorly water-soluble drug silybin by sodium cholate/phospholipid-mixed micelles Acta Pharmacol Sin 31 2010 759 764
33. R. Mellaerts, M.B.J. Roeffaers, K. Houthoofd, M. Van Speybroeck, G. De Cremer, and J.A.G. Jammaer Molecular organization of hydrophobic molecules and co-adsorbed water in SBA-15 ordered mesoporous silica material Phys Chem Chem Phys 13 2011 2706 2713
34. A. Sousa, K. Souza, and E. Sousa Mesoporous silica/apatite nanocomposite: special synthesis route to control local drug delivery Acta Biomater 4 2008 671 679
35. S. Kapoor, R. Hegde, and A.J. Bhattacharyya Influence of surface chemistry of mesoporous alumina with wide pore distribution on controlled drug release J Controlled Release 140 2009 34 39
36. Goodman LP, Bizub D. Gel system for oral and topical administration of water insoluble and/or water intolerant drugs and supplements. US Patent No. 6617356; 2003.
37. P. Morazzoni, A. Montalbetti, S. Malandrino, and G. Pifferi Comparative pharmacokinetics of silipide and silymarin in rats Eur J Drug Metab Pharmacokinet 18 1993 289 297
38. Z.Z. Li, S.A. Xu, L.X. Wen, F. Liu, A.Q. Liu, and Q. Wang Controlled release of avermectin from porous hollow silica nanoparticles: influence of shell thickness on loading efficiency, UV-shielding property and release J Controlled Release 111 2006 81 88
39. A.M. Kaukonen, L. Laitinen, J. Salonen, J. Tuura, T. Heikkil, and T. Limnell Enhanced in vitro permeation of furosemide loaded into thermally carbonized mesoporous silicon (TCPSi) microparticles Eur J Pharm Biopharm 66 2007 348 356
40. J. Brouwers, M.E. Brewster, and P. Augustijns Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J Pharm Sci 98 2009 2549 2572